Four selected phase 2 and phase 3 reports examine survodutide in obesity and liver disease. Weight, MRI liver-fat and histological endpoints are different outcomes and should not be treated as interchangeable.↗↗↗↗
What the reviewed sources report
Selected studies reported improvements in weight or liver-related measurements. The newer phase 3 reports also found frequent gastrointestinal adverse events. These measured changes do not establish every long-term clinical benefit, and linked correction notices remain relevant to interpretation.↗↗↗↗
What remains unresolved?
Do Phase 3 trials confirm durable clinical outcomes, clarify fibrosis effects, and characterize harms across broader populations?↗↗
How do participant flow, missing outcomes, protocol history and linked corrections affect interpretation of the selected reports?↗↗↗↗
Reviews summarize selected studies; their scope and limitations are shown above.
Research coverage and study families
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.
80 retrieved · 4 included · 0 excluded · 76 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"Survodutide"[Title/Abstract] OR "BI 456906"[Title/Abstract]
Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.
Linked correction notices require comparison with the selected reports: PMID41421369 for PMID38330987. Their presence does not establish what changed.
The selected newer trials are not a completed screen of this entire title/abstract search. Additional primary, secondary, safety and protocol reports remain to be appraised.
Showing 25 of 80 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 42253238 — include: Selected primary trial report; the abstract and record metadata were read. Inclusion is not completed full-text appraisal. Study families: NCT06066515.
PubMed 42252333 — include: Selected primary trial report; the abstract and record metadata were read. Inclusion is not completed full-text appraisal. A linked publisher correction is recorded in the selected review; its interpretation requires the stated correction context. Study families: NCT06309992.
PubMed 38847460 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT04771273.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 38330987 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT04667377.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
Notice XML SHA-256 a3922bee42ceaa6890ae1b819dc443ef3984b0c5b8e7ad0aba5a34fb819b2514.
PubMed 42683980 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42642663 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42603384 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42599381 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42590128 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42568490 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42545725 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42535526 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42529769 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42331726 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42254697 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42219222 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42208956 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42192439 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41948476 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41855048 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41831171 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41787737 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41704810 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41638399 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41478576 — not screened: Name-query match awaiting clinical eligibility screening.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
1 retrieved · 0 included · 0 excluded · 1 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA 69151 — not screened: Title-name match awaiting identity and document review. P/0259/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for survodutide (EMEA- 002942-PIP02-20-M02)
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
33 retrieved · 0 included · 0 excluded · 33 awaiting a decision · 0 full-text appraisals
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
NCT06066515 lists enrollment of 726, while PMID 42253238 describes 725 participants. Participant-flow and registry-history reconciliation remains open.
NCT06309992 lists enrollment of 218; the PMID 42252333 abstract describes 216 treated participants. Enrollment and treated populations are distinct.
Showing 25 of 33 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT04667377 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07407348 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05751226 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07754461 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06066528 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06632444 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05202353 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06564441 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06309992 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06352424 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06176365 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06632457 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06077864 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06745284 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06352411 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06214741 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04771273 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07413913 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06066515 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05296733 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07071974 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07206290 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03591718 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05896384 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06492135 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Read the full Human Evidence Review
Supervised synthesis
What do selected human studies report about Survodutide?
Four selected phase 2 and phase 3 reports examine survodutide in obesity and liver disease. Weight, MRI liver-fat and histological endpoints are different outcomes and should not be treated as interchangeable.1234
Bottom line from this bounded source set
Selected studies reported improvements in weight or liver-related measurements. The newer phase 3 reports also found frequent gastrointestinal adverse events. These measured changes do not establish every long-term clinical benefit, and linked correction notices remain relevant to interpretation.1234
Reviewed study record
Phase 2 obesity trial
Design
A randomized, double-blind, placebo-controlled dose-finding Phase 2 trial assessed body-weight change over 46 weeks.1
Population
The trial treated 386 adults with overweight or obesity without diabetes across 43 centers in 12 countries.1
Outcomes reported
Reported mean body-weight change ranged from -6.2% to -14.9% across planned survodutide groups and was -2.8% with placebo. About 60% completed the treatment period, and gastrointestinal events were more frequent with survodutide.1
Limitations
The sponsor-funded trial was Phase 2, had substantial treatment-period attrition, and Crossref registers a publisher erratum with two upstream dates for the same notice. Crossref metadata alone does not describe the corrected wording.1
Reviewed study record
Phase 2 MASH and fibrosis trial
Design
A randomized, placebo-controlled Phase 2 trial assessed histologic improvement in steatohepatitis without worsening fibrosis over 48 weeks.2
Population
The trial treated 293 adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and fibrosis stages F1 through F3.2
Outcomes reported
Improvement in steatohepatitis without worsening fibrosis was reported in 43% to 62% across survodutide groups and 14% with placebo. Improvement in fibrosis by at least one stage was reported in 34% to 36% and 22%, respectively.2
Limitations
The sponsor-funded, 48-week Phase 2 trial was not designed to establish long-term liver-related clinical outcomes or uncommon harms, and the fibrosis result was a secondary endpoint.2
Reviewed study record
SYNCHRONIZE-1: phase 3 obesity study
Design
A blinded randomized placebo-controlled trial assessed percentage weight change and at least 5% weight reduction at 76 weeks, under NCT06066515.3
Population
The report describes 725 adults with obesity or overweight with a related complication, excluding diabetes.3
Outcomes reported
The treatment-regimen analysis reported mean weight changes of −12.2% and −13.0% in the active groups versus −5.4% with placebo. Gastrointestinal events occurred in 80.9% and 89.7% of active groups versus 47.9% with placebo.3
Limitations
The analysis includes treatment discontinuation and other specified intercurrent events. Weight reduction does not itself establish fewer cardiovascular events or other long-term complications. No deaths were reported.3
Reviewed study record
SYNCHRONIZE-MASLD: liver-fat and weight endpoints
Design
A blinded randomized placebo-controlled phase 3 study assessed MRI-measured liver-fat reduction and weight change at 48 weeks.4
Population
The abstract describes 216 treated adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease.4
Outcomes reported
Under the treatment-regimen analysis, 68.5% with survodutide and 28.6% with placebo reached at least 30% liver-fat reduction. Mean weight changes were −8.7% and −1.4%, respectively. Gastrointestinal adverse events were common.4
Limitations
The larger estimates in the efficacy analysis answer a different question from the treatment-regimen analysis. MRI liver fat is not a clinical liver-event outcome. A linked publisher correction is recorded with this source; follow-up was short and recruitment was limited to the United States and Spain.4
Publication update registered by CrossrefErratum ↗ · publisher metadata · December 17, 2025 and February 1, 2026. Crossref metadata identifies the notice but does not by itself explain what wording changed.
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa2401755. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1056/nejmoa2600751. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Publication update registered by CrossrefCorrection ↗ · publisher metadata · August 25, 2026. Crossref metadata identifies the notice but does not by itself explain what wording changed.
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Survodutide?
Investigational. ClinicalTrials.gov lists a Boehringer Ingelheim study as active, not recruiting, updated July 22, 2026.↗
The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.
PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
Status at observationCompleted 2Recruiting 2Not yet recruiting 1
A phase value is unavailable here for 3 selected records; this is not counted as “no phase.”
A status value is unavailable here for 3 selected records; this is not counted as a trial status.
PubMed bibliography
Publication composition
0 of 3 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Bibliography fields unavailable here for 3 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
11
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
PeptideScanner retained ClinicalTrials.gov record NCT07413913 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-15, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT06077864 at 2026-08-13T05:52:27.018Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT07754461 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide.
Counts and links describe PeptideScanner’s selected records. They are not rankings and do not establish research quality, safety, effectiveness, or medical relevance.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
These dates come from selected source records and PubMed metadata. They are not a complete or continuous timeline of research, safety, approval, or effectiveness.
Evidence summary
What the cited records say
ClinicalTrials.gov lists a Boehringer Ingelheim study as active, not recruiting, updated July 22, 2026.↗
This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.
PeptideScanner retained ClinicalTrials.gov record NCT06077864 at 2026-08-13T05:52:27.018Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was survodutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07754461 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT06632444 at 2026-08-13T05:52:27.024Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT06632457 at 2026-08-13T05:52:27.009Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07413913 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-15, and PeptideScanner's reviewed identity mapping was survodutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT06176365 at 2026-07-30T16:20:49.317Z. Its registry update date was 2026-04-30, and PeptideScanner's reviewed identity mapping was survodutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT06309992 at 2026-07-30T16:20:49.307Z. Its registry update date was 2026-04-30, and PeptideScanner's reviewed identity mapping was survodutide.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41388343 at 2026-07-30T16:25:14.127Z. PubMed recorded a metadata revision date of 2026-02-14 and an Entrez history date of 2025-12-13. PeptideScanner associated this retained record with the identity slug survodutide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41424209 at 2026-07-30T16:25:14.150Z. PubMed recorded a metadata revision date of 2026-02-10 and an Entrez history date of 2025-12-22. PeptideScanner associated this retained record with the identity slug survodutide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 40557206 at 2026-07-30T18:26:54.791Z. PubMed recorded a metadata revision date of 2025-06-25 and an Entrez history date of 2025-06-25. PeptideScanner associated this retained record with the identity slug survodutide. These dates describe PubMed metadata history, not the article's original publication date.↗